Morphine Drugs Market Report 2026

The morphine drugs market size has grown strongly in recent years. It will grow from $23.09 billion in 2025 to $24.51 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to longstanding clinical reliance on morphine for severe pain relief, widespread use in post-surgical and trauma care, established role in cancer pain management, inclusion in essential medicines lists, availability of multiple generic morphine formulations.

The morphine drugs market size is expected to see strong growth in the next few years. It will grow to $30.17 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising cancer prevalence requiring strong analgesics, growing demand for palliative care services, expansion of hospital infrastructure in emerging markets, continued need for anesthesia and perioperative pain control, balanced opioid use under stricter regulatory frameworks. Major trends in the forecast period include sustained demand for opioid analgesics in severe pain management, continued use of morphine in palliative and end-of-life care, preference for injectable morphine in hospital settings, availability of multiple dosage forms for clinical flexibility, growing emphasis on controlled and regulated opioid prescribing.

The rising prevalence of chronic pain conditions is anticipated to drive the growth of the morphine drugs market in the coming years. Chronic pain is a multifaceted condition marked by ongoing discomfort that persists over a long duration and acts as an indicator of injury or disease. It has become a significant global health issue due to several interconnected factors, including aging populations, increasing obesity levels, inactive lifestyles, stress and mental health challenges, and environmental influences. Morphine plays a vital role in managing chronic pain because it is highly effective in pain relief and can be tailored to address the individual needs of patients. It improves quality of life and allows people living with chronic pain to function more effectively without constant severe discomfort. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, an estimated 24.3% of adults experienced chronic pain in 2023, with 8.5% amounting to roughly one-third of those affected reporting high-impact chronic pain, and women showing higher prevalence than men. Hence, the growing prevalence of chronic pain conditions is contributing to the expansion of the morphine drug market.

Major companies active in the morphine drug sector are concentrating on the development of advanced drug delivery solutions, such as prefilled syringe formats, to improve operational efficiency, increase safety, and minimize medication errors and preparation time. Prefilled syringes are sterile, single-use delivery systems that come preloaded with a predetermined dose of medication, removing the need to manually draw the drug from a vial prior to administration. For example, in April 2024, Hikma Pharmaceuticals PLC, a UK-based multinational pharmaceutical firm, introduced Morphine Sulfate Injection USP in a prefilled syringe in the U.S. market. This product offers a ready-to-administer, sterile form of the opioid analgesic, improving convenience for healthcare professionals in acute care environments. The prefilled syringe is intended to lower the risk of dosing inaccuracies and enhance workflow efficiency by reducing preparation steps.

In January 2024, CDMO Bora Pharmaceuticals Inc., a Taiwan-based pharmaceutical firm, acquired Upsher-Smith Laboratories Inc. for $210 million. This acquisition is intended to reinforce Bora’s presence in the generics segment by broadening its product portfolio, enhancing manufacturing capabilities, encouraging innovation, and enabling expansion into new geographic regions. Upsher-Smith Laboratories Inc. is a US-based pharmaceutical company engaged in the production of morphine drugs.

Major companies operating in the morphine drugs market are Pfizer Inc., Sanofi S.A., Rusan Pharma Ltd., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sandoz AG, Viatris Inc., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Johnson Matthey Fine Chemicals, Fresenius Kabi USA LLC, Delpharm SaS, Alvogen Inc., Mallinckrodt Pharmaceuticals, Lannett Company, Mayne Pharma Group Limited, Noramco Inc., Tasmanian Alkaloids, Napp Pharmaceuticals Limited, Alcaliber SA.

North America was the largest region in the morphine drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the morphine drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the morphine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the morphine drugs market by increasing costs associated with the import of raw opium derivatives, active pharmaceutical ingredients, and specialized manufacturing inputs. These impacts are most pronounced in regions dependent on international sourcing, particularly North America and Europe. Higher input costs have pressured pricing and supply planning for generic manufacturers. At the same time, tariffs have encouraged domestic production, local sourcing, and tighter supply chain controls to ensure drug availability.

The morphine drugs market research report is one of a series of new reports that provides morphine drugs market statistics, including morphine drugs industry global market size, regional shares, competitors with a morphine drugs market share, detailed morphine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the morphine drugs industry. This morphine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Morphine drugs are a category of medications that include morphine, a powerful opioid pain-relieving substance obtained from the opium poppy plant. These drugs are used to manage moderate to severe pain, often following surgery or injury, or in the treatment of conditions such as cancer.

The primary dosage forms of morphine medications include injectable, oral, and other formulations. Injectables are drugs or substances designed to be delivered directly into the body through injection, allowing rapid action by avoiding the digestive system. The different distribution channels comprise hospital pharmacies, retail pharmacies, and online pharmacies, serving multiple applications such as pain management, palliative care, diarrhea control, anesthesia, cold and cough relief, and others, and are utilized by various end users including hospitals and clinics, ambulatory surgical centers, and others.

The morphine drugs market consists of sales of morphine sulfate, Roxanol oral solution, Kadian capsules, morphine injections, and Avinza capsules. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.